Pinned Tweet
Our latest review is out now on targeting #BreastCancer #Immunity #tme #trm #CancerResearch many thanks to @NatureRevCancer
@PeterMacCC @PeterMacRes @TILsWorkGroup
@PeterMacCC @PeterMacRes @TILsWorkGroup
Towards targeting the breast cancer immune microenvironment dlvr.it/T9C7GF
2
11
48
11,620
Sherene Loi, MD retweeted
Sherene Loi @LoiSher offers a succinct review of the ADCs presented this AM & what we know about payload resistance at #ESMO26 @OncoAlert
0
7
12
569
Excellent rapid oral session 2 in #advancedbreastcancer today
New advances in #ADC, #CNS treatment in #HER2 #BreastCancer #ESMO26 #ESMOAmbassadors
New advances in #ADC, #CNS treatment in #HER2 #BreastCancer #ESMO26 #ESMOAmbassadors
#ESMO26: Practice-changing improvement in intracranial progression-free survival seen with the addition of tucatinib to standard therapy in HER2-positive metastatic #BreastCancer (#MBC) in the BRIDGET #ClinicalTrial.
Read more ow.ly/Gc4550ZZO6K
#InsightsbyESMO
0
5
16
1,150
Sherene Loi, MD retweeted
Interest is growing in multispecific antibodies to target tumour types that are unresponsive to current #immunotherapy, as illustrated by #ClinicalTrials presented at #ESMO26 in #ColorectalCancer and #ClearCellRenalCellCarcinoma
🔗 ow.ly/Q2vW50ZZsq4
#InsightsbyESMO
@MdCurioni
🔗 ow.ly/Q2vW50ZZsq4
#InsightsbyESMO
@MdCurioni
0
5
7
1,919
#keynoteB49- @myESMO #ESMO26
Adding ICB/ immunotherapy in advanced HR+ #breastcancer - wishful thinking 🤔 this context is immune deplete! -PFS 6-6.7 mo
➡️ Early high grade immune + HR + BC is the right place for it
#ESMOAmbassadors
Adding ICB/ immunotherapy in advanced HR+ #breastcancer - wishful thinking 🤔 this context is immune deplete! -PFS 6-6.7 mo
➡️ Early high grade immune + HR + BC is the right place for it
#ESMOAmbassadors
#ESMO26: Pembrolizumab plus chemotherapy reduced the risk of PFS by 26% in PD-L1-positive, HR-positive #AdvancedBreastCancer after failure on endocrine therapy in the phase III KEYNOTE-B49
🔗 ow.ly/5NoZ50ZZjCH
#ClinicalTrial #BreastCancer #InsightsbyESMO
@PTarantinoMD
1
1
3
417
#ESMO2026
PostMonarch - change to Fulvestrant v placebo with Abema- continues to show better PFS and OS
➡️ results by ESR1 status eagerly awaited!
#ESMOAmbassadors @OncoAlert
Published online in @Annals_Oncology
PostMonarch - change to Fulvestrant v placebo with Abema- continues to show better PFS and OS
➡️ results by ESR1 status eagerly awaited!
#ESMOAmbassadors @OncoAlert
Published online in @Annals_Oncology
0
8
10
961
🎉The only agent that can really increase pCR in a subset of early HR+ #BreastCancer is #ICB
#ESMO2026 #ESMOAmbassadors
#ESMO2026 #ESMOAmbassadors
#ESMO26: Final results from the TALENT #ClinicalTrial show low pathological complete response rates with the antibody–drug conjugate (#ADC) trastuzumab deruxtecan in HR-positive, HER2-low #EarlyBreastCancer, as discussed by @breastDoktor #InsightsbyESMO
➡️ ow.ly/ZBwi50ZZXLm
0
2
6
424
Sherene Loi, MD retweeted
Giredastrant improved IDFS and had a better tolerability (less arthralgia) compared to AI
#ESMO26
#ESMOAmbassadors
#ESMOcommunity
@myESMO @GustavoWerutsky
#ESMO26
#ESMOAmbassadors
#ESMOcommunity
@myESMO @GustavoWerutsky
1
9
23
865
#ESMO2026
Panku-breast01
Izabren sig. improves PFS in met HR+HER2 post CDK4i
#BreastCancer
👏New targets 🎈impressive ORR too
➡️broadly comparable to DB04 - here all HER2
But 🎈haem tox
Still have the what next issue 🤷🏻♀️
Online publication in @TheLancetOncol @OncoAlert @myESMO
Panku-breast01
Izabren sig. improves PFS in met HR+HER2 post CDK4i
#BreastCancer
👏New targets 🎈impressive ORR too
➡️broadly comparable to DB04 - here all HER2
But 🎈haem tox
Still have the what next issue 🤷🏻♀️
Online publication in @TheLancetOncol @OncoAlert @myESMO
0
6
12
696
#ESMO26
Natalee 6 year data with improvement in OS including in node negative & no prior chemo patients - with online publication in @Annals_Oncology
#bcsm #ESMOAmbassadors
@OncoAlert
Natalee 6 year data with improvement in OS including in node negative & no prior chemo patients - with online publication in @Annals_Oncology
#bcsm #ESMOAmbassadors
@OncoAlert
0
6
11
575
Why CD4+ T cells matter in adoptive cell therapy for solid cancers -well worth a read
esmoiotech.org/article/S2590-…
@myESMO @esmo_iotech #immunoncology #adoptivecelltherapy
esmoiotech.org/article/S2590-…
@myESMO @esmo_iotech #immunoncology #adoptivecelltherapy
0
1
6
750
Sherene Loi, MD retweeted
How should immunotherapy be optimally applied for breast cancer? Excellent review of all the work being done in this field, and emphasis of the patient, not just the tumor, immune status (see Figure B below) @jclinicalinvest
jci.org/articles/view/…
jci.org/articles/view/…
4
44
164
28,916
Brillant summary 👏 thank you 🙏 @NeilVasan
A paradigm changing decision and much food for thought @OncoAlert
A paradigm changing decision and much food for thought @OncoAlert
Live tweeting on the @FDA AdComm on @GrailBio Galleri.
Right off the bat CEO Josh Ofman emphasizing 1) the cancer types we *don’t* have screening tests for, 2) idea of cancer signal recognition independent of cancer type, 3) favorable risk/benefit mirroring voting question language, 4) concept of cancer yield, 5) adding Galleri to conventional screening
1
4
4
1,429